Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$65.39 – $83.00
100% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.60B | $2.78B | $3.41B | $3.33B | $3.05B | $3.37B | $3.37B | $3.48B |
| Cost of revenue | $1.49B | $1.59B | $1.80B | $1.79B | $1.81B | $1.91B | $1.86B | $1.97B |
| Gross profit | $1.11B | $1.19B | $1.61B | $1.54B | $1.24B | $1.46B | $1.51B | $1.51B |
| Gross margin | 42.7% | 42.7% | 47.2% | 46.3% | 40.7% | 43.3% | 44.9% | 43.5% |
| R&D | $252.2M | $263.7M | $289.6M | $328.6M | $343.5M | $325.4M | $333.1M | $319.3M |
| Operating income | $64.1M | $82.6M | $411.5M | $277.7M | −$79.8M | $184.1M | $180.0M | $238.2M |
| EBITDA | $146.0M | $197.4M | $524.4M | $425.8M | $62.6M | $257.7M | $246.7M | $384.7M |
| Net income | $34.4M | $33.4M | $188.6M | $154.2M | −$64.6M | $110.4M | $124.4M | $139.4M |
| Net margin | 1.3% | 1.2% | 5.5% | 4.6% | -2.1% | 3.3% | 3.7% | 4.0% |
| EPS (diluted) | 1.93 | 1.40 | 10.22 | 7.16 | -3.47 | 5.89 | 6.61 | 7.44 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $3.6B | $8.19 | $7.97–$8.41 | 1 |
| 2027 | $3.8B | $9.24 | $8.99–$9.49 | 1 |
| 2028 | $3.9B | $10.28 | $10.00–$10.56 | 1 |
| 2029 | $3.9B | $10.78 | $10.49–$11.07 | 1 |
Forward consensus · source: Financial Modeling Prep
DRAEGERWERK AG ORD
No one on the platform currently holds DGWPF.
No tracked institution reports a position in DGWPF as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-05-12 | $2.2100 | 2026-05-13 |
| 2025-05-13 | $1.9700 | 2025-05-14 |
| 2024-05-09 | $1.7400 | 2024-05-13 |
No one on the platform has traded DGWPF yet.
| $1.2B |
| — |
| CMPVFCompuGroup Medical SE & Co. KGaA | $33.66 | +11.64% | $1.7B | — |
| CSWYFChina Shineway Pharmaceutical Group Limited | $1.00 | +0.00% | $758M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 13.6× earnings vs its 7.5× historical median P/E.
Fair value ≈ $46.15 · price $83.00 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.